Main study parameters/endpoints: The primary study parameter is the number of days that anti-GBM antibody titre is above a toxic level, defined as >30 ELISA units. Plasma levels of anti-GBM will be measured before and after each immunoadsorption treatment. Courses of anti-GBM titres will be compared with an historical cohort of patients with anti-GBM disease treated with plasma exchange. Secondary study parameters are: 1. Tolerability and adverse events of immunoadsorption. 2. Logistic feasibility defined as the time interval between diagnosis and start of first immunoadsorption treatment; 3. Costs of immunoadsorption (personnel and materials).